Merck & Company Inc.

110.17+1.56+1.44%Vol 1.66M1Y Perf 21.38%
Jun 8th, 2023 10:43 DELAYED
BID110.16 ASK110.19
Open108.31 Previous Close108.61
Pre-Market108.63 After-Market-
 0.02 0.02%  - -
Target Price
115.93 
Analyst Rating
Strong Buy 1.44
Potential %
5.22 
Finscreener Ranking
★★+     46.87
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★+     47.83
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★★     57.37
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
★★+     43.52
Price Range Ratio 52W %
74.10 
Earnings Rating
Strong Buy
Market Cap279.55B 
Earnings Date
27th Jul 2023
Alpha0.01 Standard Deviation0.06
Beta0.35 

Today's Price Range

108.00110.27

52W Range

83.05119.65

5 Year PE Ratio Range

16.3087.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.09%
1 Month
-8.25%
3 Months
0.30%
6 Months
-2.02%
1 Year
21.38%
3 Years
31.01%
5 Years
73.55%
10 Years
144.50%

TickerPriceChg.Chg.%
MRK110.171.56131.44
AAPL178.770.94990.53
GOOG122.67-0.2700-0.22
MSFT324.881.50010.46
XOM108.47-0.0650-0.06
WFC41.77-0.3050-0.72
JNJ158.850.33000.21
FB---
GE106.150.06790.06
JPM139.85-0.8400-0.60
ProfitabilityValueIndustryS&P 500US Markets
70.50
30.10
36.70
13.60
25.32
RevenueValueIndustryS&P 500US Markets
45.45B
17.93
5.02
5.38
DividendsValueIndustryS&P 500US Markets
2.65
2.92
7.86
7.89
Payout ratio104.00
Earnings HistoryEstimateReportedSurprise %
Q01 20231.341.404.48
Q04 20221.561.623.85
Q03 20221.671.8510.78
Q02 20221.671.8711.98
Q01 20221.812.1418.23
Q04 20211.461.8023.29
Q03 20211.541.7513.64
Q02 20211.331.31-1.50
Earnings Per EndEstimateRevision %Trend
6/2023 QR1.856.32Positive
9/2023 QR1.980.00-
12/2023 FY6.951.16Positive
12/2024 FY8.46-1.17Negative
Next Report Date27th Jul 2023
Estimated EPS Next Report1.85
Estimates Count8
EPS Growth Next 5 Years %8.30
Volume Overview
Volume1.66M
Shares Outstanding2.54M
Shares Float2.53B
Trades Count21.09K
Dollar Volume181.07M
Avg. Volume6.78M
Avg. Weekly Volume7.03M
Avg. Monthly Volume6.31M
Avg. Quarterly Volume7.00M

Merck & Company Inc. (NYSE: MRK) stock closed at 108.61 per share at the end of the most recent trading day (a -1.27% change compared to the prior day closing price) with a volume of 11.64M shares and market capitalization of 279.55B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 74000 people. Merck & Company Inc. CEO is Robert M. Davis.

The one-year performance of Merck & Company Inc. stock is 21.38%, while year-to-date (YTD) performance is -2.11%. MRK stock has a five-year performance of 73.55%. Its 52-week range is between 83.05 and 119.65, which gives MRK stock a 52-week price range ratio of 74.10%

Merck & Company Inc. currently has a PE ratio of 19.10, a price-to-book (PB) ratio of 6.55, a price-to-sale (PS) ratio of 6.16, a price to cashflow ratio of 14.80, a PEG ratio of 2.32, a ROA of 16.38%, a ROC of 23.41% and a ROE of 40.81%. The company’s profit margin is 25.32%, its EBITDA margin is 36.70%, and its revenue ttm is $45.45 Billion , which makes it $17.93 revenue per share.

Of the last four earnings reports from Merck & Company Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.85 for the next earnings report. Merck & Company Inc.’s next earnings report date is 27th Jul 2023.

The consensus rating of Wall Street analysts for Merck & Company Inc. is Strong Buy (1.44), with a target price of $115.93, which is +5.22% compared to the current price. The earnings rating for Merck & Company Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Merck & Company Inc. has a dividend yield of 2.65% with a dividend per share of $2.92 and a payout ratio of 104.00%.

Merck & Company Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 8.82, ATR14 : 2.32, CCI20 : -151.44, Chaikin Money Flow : -0.09, MACD : -1.20, Money Flow Index : 41.52, ROC : -5.96, RSI : 35.58, STOCH (14,3) : 17.04, STOCH RSI : 0.27, UO : 43.80, Williams %R : -82.96), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Merck & Company Inc. in the last 12-months were: David Michael Williams (Option Excercise at a value of $128 598), Jannie Oosthuizen (Option Excercise at a value of $184 006), Jannie Oosthuizen (Sold 54 622 shares of value $5 445 371 ), Jennifer Zachary (Option Excercise at a value of $4 227 433), Jennifer Zachary (Sold 240 691 shares of value $24 205 655 ), Joseph Romanelli (Sold 5 000 shares of value $541 101 ), Kenneth C. Frazier (Option Excercise at a value of $0), Kenneth C. Frazier (Sold 2 172 853 shares of value $216 848 622 ), Richard R. DeLuca (Option Excercise at a value of $0), Richard R. DeLuca (Sold 164 557 shares of value $16 499 094 ), Rita A. Karachun (Option Excercise at a value of $0), Rita A. Karachun (Sold 31 997 shares of value $3 210 684 ), Robert M. Davis (Option Excercise at a value of $0), Robert M. Davis (Sold 167 613 shares of value $17 169 839 ), Sanat Chattopadhyay (Option Excercise at a value of $12 368 125), Sanat Chattopadhyay (Sold 250 449 shares of value $27 084 010 ), Steven C. Mizell (Option Excercise at a value of $0), Steven C. Mizell (Sold 71 251 shares of value $7 227 494 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
14 (77.78 %)
14 (77.78 %)
12 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (22.22 %)
4 (22.22 %)
3 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.44
Strong Buy
1.44
Strong Buy
1.40

Merck & Company Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the firm's sales are generated in the United States.

CEO: Robert M. Davis

Telephone: +1 908 740-4000

Address: 2000 Galloping Hill Road, Kenilworth 07033, NJ, US

Number of employees: 74 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

60%40%

Bearish Bullish

53%47%

Bearish Bullish

59%41%

Bearish Bullish

63%37%

 

TipRanks News for MRK

Wed, 07 Jun 2023 09:55 GMT Merck & Company (MRK) Gets a Buy from SVB Securities

- TipRanks. All rights reserved.

Mon, 05 Jun 2023 11:15 GMT Merck & Company (MRK) Gets a Hold from BMO Capital

- TipRanks. All rights reserved.

Tue, 30 May 2023 16:30 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Rain Therapeutics (RAIN), Merck & Company (MRK) and Lexicon Pharmaceuticals (LXRX)

- TipRanks. All rights reserved.

Mon, 01 May 2023 16:31 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Day One Biopharmaceuticals (DAWN)

- TipRanks. All rights reserved.

Mon, 01 May 2023 09:30 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Dexcom (DXCM)

- TipRanks. All rights reserved.

Fri, 28 Apr 2023 09:25 GMT Merck & Company (MRK) Receives a Hold from Morgan Stanley

- TipRanks. All rights reserved.

Tue, 18 Apr 2023 12:39 GMT Merck & Company (MRK) Gets a Buy from Jefferies

- TipRanks. All rights reserved.

Mon, 17 Apr 2023 10:35 GMT Merck & Company (MRK) Receives a Hold from Wells Fargo

- TipRanks. All rights reserved.

Mon, 17 Apr 2023 10:25 GMT Merck & Company (MRK) Receives a Buy from Citigroup

- TipRanks. All rights reserved.

Mon, 17 Apr 2023 03:15 GMT Merck & Company (MRK) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

Sun, 16 Apr 2023 10:12 GMT Merck on the Verge of Prometheus Acquisition Report

- TipRanks. All rights reserved.

Thu, 13 Apr 2023 08:25 GMT Merck & Company (MRK) was upgraded to a Buy Rating at Citigroup

- TipRanks. All rights reserved.

Mon, 10 Apr 2023 08:15 GMT Merck & Company (MRK) Gets a Buy from Mizuho Securities

- TipRanks. All rights reserved.

Fri, 17 Mar 2023 09:01 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Quest Diagnostics (DGX) and Fusion Pharmaceuticals (FUSN)

- TipRanks. All rights reserved.

Tue, 07 Mar 2023 12:30 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Stoke Therapeutics (STOK) and Day One Biopharmaceuticals (DAWN)

- TipRanks. All rights reserved.

Tue, 07 Mar 2023 10:45 GMT Merck & Company (MRK) Receives a Buy from Bank of America Securities

- TipRanks. All rights reserved.

Tue, 07 Mar 2023 09:50 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Adaptimmune Therapeutics (ADAP)

- TipRanks. All rights reserved.

Fri, 03 Feb 2023 11:05 GMT Merck & Company (MRK) Gets a Buy from Bank of America Securities

- TipRanks. All rights reserved.

News

Stocktwits